Effects of In-Home Addiction Treatment for First Responders

Effects of an In-Home Treatment Program for First Responders With Substance Use Disorder: A Retrospective Analysis

Retrospective analysis to evaluate impact of an in-home addiction treatment program on first responders with substance use disorder.

Study Overview

Status

Suspended

Detailed Description

The purpose of this retrospective study is to evaluate the effects of in-home addiction treatment on first responders with substance use disorder. Treatment engagement, hospitalizations, detox and residential addiction treatment admissions, and lethal overdoses will be measured. Although not the primary focus, recidivism and relapse will be measured.

Study Type

Observational

Enrollment (Actual)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Connecticut
      • North Haven, Connecticut, United States, 06473
        • Aware Recovery Care

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Approximately 15 individuals with substance use disorder who are or have served as a first responder (police officer, fire fighter, corrections officer, military police, emergency medical technician, paramedic, parole or probation officer) and were enrolled in Aware Recovery Care's In-Home Addiction Treatment program between April 2017 and March 2019.

Description

Inclusion Criteria:

  • Client is or has been a first responder
  • Client enrolled in Aware Recovery Care after April 2017
  • Client discharged from Aware Recovery Care before March 2019
  • Client has primary substance use disorder diagnosis

Exclusion Criteria:

  • Client has never been first responder
  • Client moved out of service area or lost insurance during care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
First Responders in In-Home Addiction Treatment Program
- First responders (individual who does or has worked as a police officer, fire fighter, corrections officer, military police, emergency medical technician, paramedic, parole or probation officer)
  • Treatment was delivered per treatment protocol
  • Primary IHAT Care Team consisted of a licensed Care Coordinator (LPN, RN, MSW, LPC, or LMFT) and two Recovery Advisors
  • Urine drug screens administered randomly
  • Appointments were scheduled per protocol for 52 weeks
  • Within first two weeks of care, all clients are provided an evaluation by a psychiatrist to ensure fitness for program

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of Retention in Treatment
Time Frame: Measured throughout 365 day duration of anticipated length of stay
Participation in In-Home Addiction Treatment Program using length of stay reports
Measured throughout 365 day duration of anticipated length of stay
Brief Addiction Monitor questionnaire
Time Frame: Conducted monthly throughout 365 day anticipated length of stay in program
Measure change in client report of symptoms related to substance use disorder
Conducted monthly throughout 365 day anticipated length of stay in program
Positive Outcomes Measures Survey
Time Frame: Completed at week 3 or 4, Week 30, Week 35, Week 44, and Week 50 throughout 52 week anticipated length of program participation
Measures changes in quality of life using client self-report inquiring about employment, connection to care team, community engagement using yes/no/not applicable response scale
Completed at week 3 or 4, Week 30, Week 35, Week 44, and Week 50 throughout 52 week anticipated length of program participation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relapse rates
Time Frame: Randomly administered throughout 365 day anticipated length of program participation
Occurrence of substance use measured through urine drug screening and breathalyzer tests
Randomly administered throughout 365 day anticipated length of program participation
Hospitalization
Time Frame: Measured throughout 365 day anticipated length of program participation
Occurrence of Emergency Room and Inpatient hospital admissions
Measured throughout 365 day anticipated length of program participation
Detox and Residential Admissions
Time Frame: Measured throughout 365 day anticipated length of program participation
Occurrence of residential treatment and detox admission
Measured throughout 365 day anticipated length of program participation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sara Kaiser, MS Ed, LPN, In-Home Addiction Treatment Institute, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 8, 2019

Primary Completion (Anticipated)

May 28, 2020

Study Completion (Anticipated)

July 28, 2020

Study Registration Dates

First Submitted

April 5, 2019

First Submitted That Met QC Criteria

April 5, 2019

First Posted (Actual)

April 9, 2019

Study Record Updates

Last Update Posted (Actual)

August 7, 2019

Last Update Submitted That Met QC Criteria

August 5, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • IHATI-2019-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Substance Use Disorders

Clinical Trials on In-Home Addiction Treatment Program

3
Subscribe